PMCF_AWR: Safety and Clinical Performance of a Biological Matrix Used in Abdominal Wall Reconstruction
Study Details
Study Description
Brief Summary
The general objective of the study is to confirm the medium/long-term safety and clinical performance of the CELLIS membrane used in abdominal wall reconstruction including, but not limited to, ventral hernia repair and stoma closure, and to identify emerging risks in comparison to the clinical data related to other types of fixation material.
The present study will be a prospective multicentric non-randomized and noncontrolled trial involving 112 patients followed for 24 months. The study will be conducted in France in 3 investigational centres.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
The study will be prospective, multicentric, single-arm, observational (non-interventional) to evaluate the safety and performance of the CELLIS membrane used in abdominal wall reconstruction including, but not limited to, ventral hernia repair and stoma closure.
All evaluations will be performed and products used according to the usual practice, without additional or unusual diagnostic, treatment and monitoring procedure.
The study will be conducted in France in 3 investigational centres including 112 patients scheduled for an abdominal wall reconstruction.
Each patient will participate in one assessment period including a preoperative visit, followed by the day of surgical procedure and a hospitalization period.
Patients will return for ambulatory visits on day 30 (+/- 7 days), on month 3 (+/- 2 weeks), on month 12 (+/- 2 weeks) and on month 24 (+/-2 weeks) post-surgery.
CELLIS will be implanted by open technique following standard techniques. The membrane can be used in bridged or reinforced repairs. Mesh placement can include inlay (bridging), underlay intraperitoneal, sublay (retrorectus/retromuscular) positions.
Study Design
Outcome Measures
Primary Outcome Measures
- Rate of adverse events including reoperation and removal of the mesh. The main complications of interest are Surgical Site Occurrence (SSO) including Surgical Site Infection (SSI). [From the surgical procedure throughout the entire 24-month follow-up period]
Percentage
Secondary Outcome Measures
- Rate of recurrence/incisional hernia evaluated by clinical examination and/or CT-scan [Throughout the study until end of the 24-month follow-up period]
Percentage
- Rate of recurrence/incisional hernia requiring reoperation [Throughout the study until end of the 24-month follow-up period]
Percentage
- Rate of abdominal wall laxity [Throughout the study until end of the 24-month follow-up period]
Percentage
- Description of device deficiency: inadequacy of a medical device with respect to its identity, quality, durability, reliability, safety or performance. Device deficiencies include malfunctions, use errors, and inadequate labelling. [During the surgical procedure]
Summarized and listed
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patient aged ≥18 years,
-
Patient with an indication of abdominal wall reconstruction including, but not limited to, ventral hernia repair and stoma closure,
-
Patient being informed of its participation to the study and of the follow-up visits, and having no objection to the clinical data collection and medical file access,
-
Patient being informed of the porcine origin of the device in advance of the procedure.
Exclusion Criteria:
-
Patient with known hypersensitivity to porcine materials,
-
Patient who is pregnant,
-
Patient having refused to participate to the study,
-
Patient refusing to return for the follow-up visits.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | CHU Caen Normandie, Service de Chirurgie Digestive | Caen | France | ||
| 2 | Groupe Hospitalier La Rochelle - Ré - Aunis | La Rochelle | France | ||
| 3 | CHU Montpellier, Hôpital Saint-Eloi, Pôle digestif, Service de Chirurgie Digestive B et Transplantation | Montpellier | France |
Sponsors and Collaborators
- Meccellis Biotech
Investigators
- Principal Investigator: Hassan BOUYABRINE, MD, CHU Montpellier, France
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- AWR_01_CIP